AcelRx Pharmaceuticals, Inc. (ACRX) saw its loss narrow to $9.68 million, or $0.21 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $10.55 million, or $0.24 a share. Revenue during the quarter surged 271.97 percent to $6.44 million from $1.73 million in the previous year period. Gross margin for the quarter period stood at positive 50.88 percent as compared to a negative 2.31 percent for the previous year period.
Operating loss for the quarter was $7.14 million, compared with an operating loss of $7.54 million in the previous year period.
"We have taken meaningful steps towards meeting our goal of DSUVIA approval in the U.S., and we continue to make additional commercial preparations for a potential DSUVIA launch," commented Howie Rosen, chief executive officer. Mr. Rosen continued. "A key aspect of our preparations, as we announced a few weeks ago, is having appointed Vincent J. Angotti to be chief executive officer starting March 6th.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]